Pharma BD Deal Intelligence

Mylan Inc. / Famy Care Limited (women's healthcare businesses)

2015 · Asset Purchase · $800M · Complete

Announcement Sentiment

Strongly positive

Mylan agreed to acquire certain women's healthcare businesses from Famy Care for $750M cash plus up to $50M contingent payments. Famy Care was the world's largest producer of generic OCPs. Acquisition closed November 20, 2015 via Mylan Laboratories Limited subsidiary.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Neutral

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Feb 02, 2015
Closed Nov 20, 2015
Deal value $800M
Deal type Asset Purchase
Therapeutic area Women's health / contraception
Indications Women's health / contraception
Key assets Generic oral contraceptive portfolio
Mechanism Hormonal contraceptives (varied)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals